Myeloma Research News

February 22, 2021February 22, 2021

Xpovio Open to Advanced Myeloma Patients Outside US via Access Program

Myeloma Research News

People with advanced multiple myeloma and diffuse large B-cell lymphoma (DLBCL) will soon be able to access Xpovio (selinexor) outside the U.S. through a managed access program. This program, also known as ... Read more

February 19, 2021February 19, 2021

C4 Therapeutics Readying to Open Phase 1/2a Trial of CFT7455

Myeloma Research News

C4 Therapeutics is preparing to launch a clinical trial testing its lead investigational therapy CFT7455 in multiple myeloma and other blood cancers. The U.S. Food and Drug Administration (FDA) approved ... Read more

February 17, 2021February 17, 2021

Blood Type O Lowers Myeloma Risk, But Outcomes Typically Worse

Myeloma Research News

People with blood type O are significantly less likely to develop multiple myeloma, but those who do are likely to have more aggressive disease and poorer survival outcomes, a study ... Read more

February 15, 2021February 16, 2021

Darzalex Combos Linked to Stronger Cancer Eradication, Prolonged Survival

Myeloma Research News

Adding Darzalex (daratumumab) to standard regimens for adults with relapsed or refractory multiple myeloma resulted in higher rates of deep and durable responses, according to exploratory analyses of two Phase ... Read more

February 12, 2021February 12, 2021

Xpovio Approved in Israel for Some Myeloma, Lymphoma Patients

Myeloma Research News

The Israeli Ministry of Health has approved Xpovio (selinexor), in combination with the corticosteroid dexamethasone, for the treatment of people with multiple myeloma who have received three or more prior ... Read more

February 10, 2021February 10, 2021

FDA Clears Way for Clinical Trial of HDP-101

Myeloma Research News

Heidelberg Pharma has been cleared in the U.S. to begin a clinical trial testing its investigational therapy HDP-101 for the treatment of multiple myeloma. The U.S. Food and Drug Administration ... Read more

February 8, 2021February 9, 2021

Under-the-skin Velcade Found to Work Better in Farydak Triple Combo

Myeloma Research News

Using an under-the-skin formulation of Velcade (bortezomib), in combination with Farydak (panobinostat) and oral dexamethasone, leads to a better safety profile in people with relapsed or refractory (resistant) multiple myeloma ... Read more

February 5, 2021February 5, 2021

Phase 3 Trial of ATG-010 (Xpovio) for Advanced Myeloma Opens in China

Myeloma Research News

China’s regulatory agency has approved the start of a Phase 3 clinical trial testing ATG-010 (selinexor), in combination with Velcade (bortezomib) and dexamethasone, in multiple myeloma patients after one to three ... Read more

February 3, 2021February 3, 2021

EMA Plans Speedy Review of Cilta-cel, CAR T-cell Therapy for Advanced Myeloma

Myeloma Research News

An accelerated review will be given an application for European Union approval of ciltacabtagene autoleucel (cilta-cel), a potential CAR T-cell therapy for heavily pre-treated multiple myeloma patients, its developer, Janssen, announced. An accelerated ... Read more

February 1, 2021February 1, 2021

EU Committee Supports Nexpovio for Heavily Treated Myeloma Patients

Myeloma Research News

A combination of Nexpovio (selinexor) and the corticosteroid dexamethasone has been recommended for conditional approval in the European Union to treat adults with relapsed or refractory multiple myeloma who received at ... Read more

January 29, 2021January 29, 2021

Dosing Begins in Phase 1 Trial of CERC-007

Myeloma Research News

Cerecor has dosed the first patient in a Phase 1b clinical trial evaluating  CERC-007 as a potential treatment for relapsed or refractory multiple myeloma. The trial (NCT04671251) intends to enroll ... Read more

January 27, 2021January 27, 2021

Jakafi Plus Steroid Continuing to Treat Multiple Myeloma in Phase 1 Trial

Myeloma Research News

Combining the corticosteroid methylprednisolone and Jakafi (ruxolitinib), an approved oral therapy for bone marrow disorders, is showing promising effectiveness in heavily pre-treated multiple myeloma patients in an ongoing Phase 1 trial. ... Read more

January 25, 2021January 25, 2021

$10M Gift to Open Myeloma Research Center at Ohio State

Myeloma Research News

A new research center at Ohio State University (OSU) aims to speed work into the discovery and development of more effective treatments for those with multiple myeloma. The Riney Family Foundation ... Read more

January 22, 2021January 22, 2021

First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy

Myeloma Research News

The first patient has been dosed in Celyad Oncology’s Phase 1 clinical trial evaluating CYAD-211, an investigational donor-derived CAR T-cell therapy for treating relapsed or refractory multiple myeloma. The IMMUNICY-1 ... Read more

January 20, 2021January 20, 2021

Early Data Show TNB-383B to be Safe, Effective for Heavily Treated Myeloma

Myeloma Research News

Teneobio‘s bispecific antibody TNB-383B was found to be well-tolerated and induced a high response rate among people with heavily treated multiple myeloma in an ongoing Phase 1 trial. Preliminary data from ... Read more